The first successfulclinical application of the experimental observations about the role of therenin-angiotensin in the cardiovascular pathophysiology was the demonstration ofthe ACE inhibitors as an undisputed treatment in patients with congestive heartfailure or coronary artery disease (CAD) and concomitant left ventriculardysfunction, all clinical syndromes characterized by a strong activation of therenin-angiotensin system [119]. Here, ACE is linked to coronary artery disorder.